切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2017, Vol. 05 ›› Issue (04) : 217 -220. doi: 10.3877/cma.j.issn.2095-5820.2017.04.005

所属专题： 文献；

专题笔谈

VeriStrat在非小细胞肺癌等肿瘤个体化治疗中的应用现状
陈锋1, 张荣2, 刘昕超2, 崔松2, 杨珺2, 马庆伟2, 陈琛2, 张晓青2, 崔巍1,†()   
  1. 1. 100021　国家癌症中心/中国医学科学院北京协和医学院肿瘤医院检验科
    2. 102206　北京毅新博创生物科技有限公司
  • 收稿日期:2017-09-26 出版日期:2017-11-28
  • 通信作者: 崔巍
  • 基金资助:
    中国医学科学院医学与健康科技创新工程项目(2017-12M-3-005)

Application of VeriStrat test in individualized treatment of non-small cell lung cancer and other tumors

Feng Chen1, Rong Zhang2, Xinchao Liu2, Song Cui2, Jun Yang2, Qingwei Ma2, Chen Chen2, Xiaoqing Zhang2, Wei Cui1,†()   

  1. 1. National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    2. Buoying Technologies Inc, Beijing 102206, China
  • Received:2017-09-26 Published:2017-11-28
  • Corresponding author: Wei Cui
  • About author:
    Corresponding author: Cui Wei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈锋, 张荣, 刘昕超, 崔松, 杨珺, 马庆伟, 陈琛, 张晓青, 崔巍. VeriStrat在非小细胞肺癌等肿瘤个体化治疗中的应用现状[J/OL]. 中华临床实验室管理电子杂志, 2017, 05(04): 217-220.

Feng Chen, Rong Zhang, Xinchao Liu, Song Cui, Jun Yang, Qingwei Ma, Chen Chen, Xiaoqing Zhang, Wei Cui. Application of VeriStrat test in individualized treatment of non-small cell lung cancer and other tumors[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2017, 05(04): 217-220.

肽谱分(VeriStrat)是一种基于血液蛋白质组学试验，用于非小细胞肺癌(non-small cell lung cancer，NSCLC)患者用药效果的预测性和预后性分类测试方法。该测试时患者被分类为VeriStrat-Good组和VeriStrat-Poor组，通过表征宿主对肿瘤的反应来评估疾病的侵袭性，还可用于NSCLC的精准医学诊断。我们对VeriStrat在临床的应用现状进行阐述，并分析探讨VeriStrat在NSCLC及其他肿瘤个体化治疗中的临床价值，以推动肿瘤个体化治疗的进步。

关键词: 非小细胞肺癌, 个体化治疗, 肿瘤, 肽谱分

The VeriStrat test is a blood-based proteomic test with predictive and prognostic significance in treatment of non-small cell lung cancer (NSCLC). Mass spectra from these patients′ serum samples were classified into two outcome groups, VeriStrat-Good group and VeriStrat-Poor group which are used to evaluate different treatment outcomes. It also cam used for precision medicime of NSCLC. Our paper illustrates the current progress in the clinical application of VeriStrat test, and aims to investigate the clinical value of Veristrat test in the treatment of NSCLC and other tumors. In summary, VeriStrat test is helpful to promote the application of individualized treatments.

Key words: Non-small cell lung cancer, Individualized treatment, Tumors, VeriStrat
1
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016,66(1):7-30.
2
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture[J]. Eur J Cancer, 2001,37 Suppl 8:S4-66.
3
宋晓燕，李积德，赵君慧. 非小细胞肺癌个体化靶向治疗进展[J]. 医药前沿, 2012(32): 27-28.
4
廉政君，黄建国. 晚期非小细胞肺癌预后相关因素分析[J]. 现代肿瘤医学, 2014,22(1): 95-97.
5
Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study[J]. J Nati Cancer Inst, 2007,99 (11):838-846.
6
Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab[J]. Lung Cancer, 2010,69(3):337-340.
7
Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib[J]. Br J Cancer, 2012,107(11):1820-1825.
8
Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors[J]. J Thorac Oncol, 2012,7(1):40-48.
9
Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non–small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial[J]. J Thorac Oncol, 2012,7(11):1653-1660.
10
Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial[J]. Lancet Oncol, 2014,15(7):713-721.
11
Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4. 2016[J]. J Nati Compr Canc Netw, 2016,14(3):255-264.
12
Grossi F, Rijavec E, Genova C, et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy[J]. Br J Cancer, 2017,116(1):36-43.
13
Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2010,19(2):358-365.
14
Mazouni C, Baggerly K, Hawke D, et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure[J]. Proteomics, 2010,10(19):3525-3532.
15
Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528[J]. Lung Cancer, 2013,79(1):59-64.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[8] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[9] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[10] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[13] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[14] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[15] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号